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Summary
Fragile X premutations are considered to be a risk factor
for premature ovarian failure (POF), which is usually
defined as menopause at age !40 years. Since premu-
tations may be inherited from either the mother or the
father, we evaluated the influence of the inheritance pat-
tern on the duration of reproductive life in female car-
riers. The occurrence of POF and age at menopause in
women with a paternally inherited fragile X premutation
(PIP) were compared to those in women with a mater-
nally inherited fragile X premutation (MIP). We iden-
tified 148 women in whom the parental origin of the
premutation could be determined. In 109 of these
women we were able to establish whether POF had oc-
curred: 82 women had a PIP, and 27 had a MIP. Twenty-
three of the women (28%) with a PIP had POF, versus
only 1 (3.7%) with a MIP (two -tailed Fisher’s exact
test; ). Kaplan-Meier analysis of all 148 pre-P = .007
mutations showed that the age at menopause was sig-
nificantly lower in the women with a PIP than in the
woman with a MIP (Breslow test in Kaplan-Meier anal-
ysis; ). Our data strongly suggest that, whenP = .003
POF occurs in fragile X premutation carriers, a consid-
erable proportion of the premutations are inherited pa-
ternally (parent-of-origin effect). We hypothesize that
this may be owing to a paternal genomic imprinting
effect.
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Introduction
The fragile X syndrome (MIM 309550) is an X-linked
disorder caused by deficiency of fragile X mental retar-
dation protein (FMRP), a deficiency that is the result of
transcriptional silencing of the FMR1 gene by a process
of methylation (Imbert et al. 1998). Methylation only
occurs when the polymorphic CGG-repeat tract in the
promoter (Verkerk et al. 1991) expands into the full
mutation range—that is, 1200 repeats; normally there
are !50 repeats. Alleles with repeat sizes of 50–200 are
classified as premutations, which are meiotically unsta-
ble and can expand to full mutations only when mater-
nally transmitted. Although FMRP is produced at nor-
mal levels by alleles in the premutation range (Feng et
al. 1995), there is growing evidence that premutations
may have an effect on the normal phenotype.
Recently, an international collaborative study of pre-
mature ovarian failure (POF) (Allingham-Hawkins et al.
1999) in fragile X carriers has reported that fragile X
premutations are a significant risk factor for POF, de-
fined as complete cessation of periods at age !40 years.
This observation is consistent with findings described in
other reports (Schwartz et al. 1994; Conway et al. 1998;
Murray et al. 1998; Uzielli et al. 1999), as well as with
those in our ongoing study. However, Kenneson et al.
(1997) screened 33 women with POF and did not find
any fragile X premutation.
There is strong evidence that premutation carriers
have an increased risk of POF. Nevertheless, the question
remains as to why some premutation carriers experience
POF whereas others do not. In our ongoing study, we
observed that POF was cosegregating with premutations
that were inherited paternally. We tested the hypothesis
that a parent-of-origin effect might be involved in the
increased risk of POF in fragile X–premutation carriers.
Subjects and Methods
Clinical and molecular data were from our study
group of families, which previously had been given di-
agnoses of fragile X syndrome. Female carriers of the
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Table 1
Female Fragile X Premutation Carriers and
Their Menstrual Cycles
NO. OF WOMEN
PIP MIP Total
Spontaneous menopause:
At age !40 years 23 1 24
At age 40 years 36 14 50
Proved ovarian function 23 12 35
Total 82 27 109
NOTE.—All women were age 40 years when
they participated in the study.
fragile X premutation, for whom the parental origin was
known, were selected. All the women were age 18
years and had a normal karyotype. They were inter-
viewed personally by the same physician; a complete
medical history was taken, including data on the repro-
ductive life span. Whenever possible, the anamnestic
data were verified from medical records, with the con-
sent of the participant. The study was approved by the
institutional review board.
In the present study, POF was defined as spontaneous
menopause at age !40 years. Spontaneous menopause
implies either spontaneous cessation of menstruation,
with a duration of 1 year, or secondary amenorrhea,
with a duration of 6 mo–1 year, with an FSH level of
140 IU/liter and low serum 17b-estradiol concentrations.
Spontaneous cessation of menstruation does not apply
to cases with termination resulting from hysterectomy,
bilateral oophorectomy, chemotherapy, radiotherapy, or
ablative medication. If a woman still had menstrual cy-
cles, her ovarian function was assessed on the basis of
serum FSH and luteinizing-hormone levels (IMx; Abbott
Laboratories) and 17b-estradiol radioimmunoassays, as
described elsewhere (Thomas et al. 1977). Women with
premenopausal endocrine profiles were categorized as
women with proved ovarian function. The age of last
menstruation was included for women who were using
oral contraceptives. The participants were divided into
two groups: women with a paternally inherited pre-
mutation (PIP) and women with a maternally inherited
premutation (MIP).
In our first analysis, women were included when we
were able to determine that POF had occurred. We ex-
cluded all women age !40 years (in accordance with the
definition of POF), all those with a history of nonspon-
taneous cessation of menstruation at age !40 years, and
all those who were using oral contraceptives at the age-
cutoff point (40th birthday). The occurrence of POF in
the group with a PIP was compared with that in the
group with a MIP. Fisher’s exact test was used to eval-
uate statistically significant differences.
To avoid loss of information on the menstrual status
of the women who either had not yet attained age 40
years who had experienced nonspontaneous cessation of
menstruation, we also used a Kaplan-Meier survival ap-
proach to compare age at menopause in women with a
PIP to that in women with a MIP. Age at the time of
participation in the study was used for the women with
proved ovarian function, whereas the age at cessation
was used for the women with nonspontaneous cessation
of menstruation. The Breslow test was used to evaluate
the age-at-menopause distributions. All analyses were
performed with Statistical Package for Social Sciences
software, version 8.0, and Statistical Analysis System
software, version 6.12.
Results
Relevant data were available on 148 female carriers
(age 118 years) from 55 families, with different pre-
mutation-repeat sizes; 106 of the women had a PIP and
42 had a MIP. The 106 women with a PIP are daughters
of, in total, 48 fathers (average 2.21 daughters, range
1–10) with a premutation, whereas the 42 women with
a MIP are daughters of, in total, 29 mothers (average
1.45, range 1–3) with a premutation.
The number of PIPs is higher because premutation
males transmit a premutation to all their daughters. Pre-
mutation females can transmit either a normal allele to
their daughters or a mutated allele that can be a full-
mutation allele or a premutation allele. All 148 women
were interviewed personally about their menstrual cycles
(i.e., whether they were still menstruating), and data
were verified on the basis of medical records. Women
were subdivided into the following four categories: those
with spontaneous menopause at age (1) !40 years or (2)
40 years, (3) those with nonspontaneous cessation of
menstruation at age !40 years, and (4) those with proved
ovarian function. Subsequently, we investigated the re-
lation between POF (at age ! 40 years), and the parental
origin of the fragile X premutation. Owing to the age-
cutoff point, data on all the women of age !40 years
( ) were excluded. Three women with a PIP andn = 30
six women with a MIP were excluded as well, because
it could not be established whether POF had occurred
(nonspontaneous cessation of menstruation). In the re-
maining 109 women (82 of whom had a PIP and 27 of
whom had a MIP), we determined whether POF had
occurred. In the group of women with a PIP, 23 (28%)
of 82 had experienced menopause at age !40 years,
whereas this had occurred in only 1 (3.7%) of the 27
women in the group with a MIP (table 1). Table 2 shows
the distribution of POF among the families with at least
one woman with POF. POF is distributed among the
kindreds and is not found exclusively in a subset of fam-
ilies. In families with at least two females with POF,
differences in age at menopause were found. No cor-
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Table 2
Distribution of POF in Families with at Least One Case of POF
FAMILY
(TRANSMISSION)
DAUGHTERS, IN BIRTH ORDERa
1 2 3 4 5 6 7 8 9 10
1 (Paternal) 
2 (Paternal) 
3 (Paternal) 
4 (Paternal)  
5 (Paternal)  
6 (Paternal)   
7 (Paternal)  
8 (Paternal)   
9 (Paternal)   
10 (Paternal)    
11 (Paternal)   
12 (Paternal)   
13 (Paternal)    
14 (Paternal)          
15 (Maternal) 
a A plus sign () denotes presence of POF; a minus sign () denotes
absence of POF.
Figure 1 Cumulative risk of menopause in women with either
a PIP (unbroken line) or a MIP (dashed line). Blackened squares denote
the censored observations (last included informative data on women
with either proved ovarian function or nonspontaneous cessation of
menstruation).
relation was seen between premutation-repeat size and
age at menopause.
Thus, POF was significantly more common in carriers
of a PIP than in carriers with a MIP (two-tailed Fisher’s
exact test; ). The odds ratio was estimated toP = .007
be 10.1 (95% confidence interval 1.3–79.1). This indi-
cates that women with a PIP have a 10-times-higher risk
of POF than do women with a MIP.
In the first analysis, 39 of 148 women were not in-
cluded. To avoid loss of information on the menstrual
status of these women, we also performed a Kaplan-
Meier survival analysis of age at menopause, which in-
cluded informative data on all the women ( ). Inn = 148
the women with nonspontaneous menopause, age at in-
tervention was used in the analysis (fig. 1). The Breslow
test for equality of survival distributions showed that
age at menopause in the group with a PIP was signifi-
cantly different than that in the group with a MIP
( ); female fragile X carriers with a PIP becameP = .003
postmenopausal at a younger age than did those with a
MIP. The calculated cumulative probabilities of meno-
pause at various ages (with use of actuarial survival tech-
niques) are given in table 3.
Discussion
We studied age at menopause and the occurrence of
POF in female fragile X carriers with either a PIP or a
MIP. The age at menopause was significantly different
between the two groups (Breslow’s test; );P = .003
women with a PIP became postmenopausal at a younger
age. Moreover, we found that 28% of the women with
a PIP had become postmenopausal spontaneously at age
!40 years and thus satisfied our strictly defined criteria
for POF. Only 1 of 27 women with a MIP had POF, a
rate that is significantly lower than that in the women
with a PIP. Sporadic cases of POF are observed in 1%
of the general female population (Coulam et al. 1986).
Therefore, it cannot be ruled out that some of our par-
ticipants (including the woman with a MIP) represented
sporadic cases of POF. Nevertheless, our data strongly
suggest that female fragile X carriers who inherit the
premutation from their fathers have an excess risk for
POF.
Table 2 shows that POF was more common in some
of our sister sets with premutations (with a maximum
of seven cases of POF in one sister set with 10 sisters)
than in others. Owing to family relatedness, the occur-
rence of POF in sister sets might be different from ex-
pectations based on a binomial distribution. Conse-
quently, the width of the 95% confidence interval of the
odds ratio, as well as the P value of the Fisher’s exact
test, may be underestimated. To evaluate this potential
bias in the variance of our estimates, we performed lo-
gistic regression analysis on our data, taking relatedness
into account and allowing for extra binomial variation.
It appeared that there was no extra binomial variation
and that the usual binomial model fitted the data well.
Age at menopause is strongly related to the number
of ovarian follicles (Ginsburg 1991). Faddy and Gosden
(1996) developed a mathematical model that relates fol-
licle depletion to age at menopause in human females.
Although POF may be associated with a normal number
of oocytes (i.e., the resistant-ovary syndrome), the most
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Table 3
Cumulative Percentages of Women with either a PIP or a MIP Who Became Postmenopausal, by Age
CUMULATIVE PERCENTAGES OF WOMEN
WHO BECAME POSTMENOPAUSAL, BY AGE
(years)
MEDIAN
SURVIVAL
(years)!25 !30 !35 !40 !45 !50 !55 !60
Women with a PIP 2.85 3.81 12.7 25.7 42.2 81.8 97.0 100 46.7
Women with a MIP .00 .00 .00 3.12 26.5 46.7 100 100 50.1
likely biological basis for POF is low follicle storage
(Gosden and Faddy 1998). Low numbers of oocytes are
caused by either deficient oogenesis or increased oocyte
loss. A considerable percentage of the women with a PIP
experienced POF. These women may have suffered from
either abnormalities in oogenesis or increased loss of
oocytes during prenatal—or, less likely, postnatal—life.
Mitochondrial function influences the reproductive
life span (Dorland et al. 1998; Eichenlaub-Ritter
1998). Since mtDNA is never inherited paternally, we
can exclude this as an explanation for POF devel-
opment in carriers with a PIP. In any case, the oocyte
pool is not likely to be small because of mitochondrial
abnormalities.
We hypothesize, on the basis of our findings, that the
paternal effect in POF in fragile X premutation carriers
can be explained by paternal genomic imprinting (ge-
nomic imprinting is an epigenetic phenomenon in which
there is unequal expression of maternal and paternal
genes in the offspring). Expression of the FMR1 gene
and other X-linked genes is nonfunctional during normal
spermatogenesis (Tamanini et al. 1997), when the X
chromosome becomes condensed and transcriptionally
inactive (Monesi et al. 1978). Most genes are reactivated
during the first few cell divisions after fertilization,
whereas two X chromosomes are active in the female
morula (Epstein et al. 1978). However, when a PIP is
imprinted, there may be a delay in reactivation of the
(inactive) paternal X chromosome during early embry-
onic development; thus, only the maternal allele would
be expressed at this critical developmental stage. At the
time of X inactivation, either the paternal X or the ma-
ternal X is randomly inactivated. Although, in half of
the cells. the paternal X is inactive, they will transcribe
the normal maternal copy, resulting in normal FMRP
expression. But, if the PIP is imprinted on the active X
chromosome, this may hinder FMR1-gene transcription
and result in reduced or complete absence of FMRP
expression. Consequently, only 50% of the cells would
have normal production, whereas the other 50% would
have either reduced levels or complete absence of FMRP
production. Although there is no direct evidence that
abnormal FMRP production in oocytes leads to a
smaller oocyte pool, it is possible that FMRP plays a
role in oogenesis, because FMRP is highly expressed
when oogenesis occurs (Ba¨chner et al. 1993). Further-
more, there is evidence that FMRP also plays a role in
spermatogenesis (Malter et al. 1997), because FMRP
production was found to be increased in type A1 sper-
matogonia. Our hypothesis predicts decreased FMRP
levels during oogenesis, which can be tested in animal
models (Dutch-Belgian Fragile X Consortium 1994); the
paternally inherited FMR1 gene is knocked out. Pater-
nally inherited FMR1 knockout alleles have resulted in
female mice that are fertile. Since mice do not show
menopause, we will test whether absence of FMR1-gene
expression in the paternal allele results in low numbers
of oocytes.
POF is not observed in full-mutation females. Our
hypothesis of paternal genomic imprinting also explains
why the occurrence of POF in women with a full mu-
tation may be expected to be similar to that in the general
population (i.e., 1%). Full mutation is always inherited
from the mother (in which case, paternal imprinting will
not take place). In early embryogenesis, a full-mutation
gene is not methylated (Malter et al. 1997) and might
be able to produce FMRP. The timing of inactivation of
the fully mutated allele is not known, but it is known
from extra embryonal tissue that inactivation of a full
mutation occurs much later than does X inactivation
(Willemsen et al. 1996).
Examples of X-chromosomal imprinting have been
described in humans. It has been suggested that a locus
on the maternally inherited X chromosome is imprinted,
thereby affecting cognitive function, in Turner syndrome
(Skuse et al. 1997). In the mouse, the paternal X chro-
mosome in the extraembryonal tissues is exclusively in-
activated (West et al. 1977). In marsupials, the paternal
X chromosome is inactivated in most if not all tissues
(Cooper 1971).
When studying the possible influence of fragile X pre-
mutations on age at menopause, we were very careful
to comply with an exact definition of POF in our group
of patients. This was essential, because menopause can
only be established either after 1 year of secondary
amenorrhea or when there is secondary amenorrhea
with a duration of 6 mo–1 year, with an FSH level of
140 IU/liter. One of the difficulties is that data usually
have to be collected retrospectively; thus recall bias may
occur. Furthermore, determination of age at menopause
Hundscheid et al.: Imprinting Effect in Premature Ovarian Failure 417
will not be reliable if data are not obtained first hand
(van Kasteren et al. 1999). Relatives do not know the
exact medical background (e.g., the termination of men-
struation because of hysterectomy at a young age) of the
members of their family, which results in “hearsay” data.
Therefore, we interviewed all the women personally, to
limit, as much as possible, the risk of misclassification.
We also checked the participants’ medical records, to
ensure that no concurrent conditions had occurred. De-
spite such precautions, the definition of POF is a major
problem in these studies. Many previously published ar-
ticles (Schwartz et al. 1994; Partington et al. 1996; Ken-
neson et al. 1997) on the relation between POF and
FMR1-gene mutations have defined POF as menopause
at age !40 years. However, it often remains unclear
whether the authors of those articles considered that
menopause was present at 13, 1 6, or 112 mo of sec-
ondary amenorrhea, with or without elevated FSH. We
would like to emphasize the importance of reaching con-
sensus on the definition of POF. Only then will it be
possible to compare the results of the various groups
working on this subject.
The cutoff point of age 40 years for POF is based on
epidemiological studies. Only 1% of women become
postmenopausal prior to that age. However, age 40 years
is an arbitrarily defined cutoff point. Women whose
menopause occurs just after 40 years of age will gen-
erally have an underlying biological basis similar to that
of individuals with POF. In this study, womenwith either
a PIP or a MIP were categorized as either POF or not
POF. Nevertheless, POF was significantly more common
in the women with a PIP than in those with a MIP. In
addition, we performed a survival analysis in which the
age at menopause did not have to be categorized. In our
opinion, this is the best approach to the study of age at
menopause. Figure 1 shows that age at menopause is
significantly different between the group with aMIP and
the group with a PIP and that the whole curve is shifted
to the left in the women with a PIP.
In conclusion, the paternal genomic-imprinting hy-
pothesis has important implications not only scientifi-
cally, but also for the counseling of premutation carriers.
Premutation carriers who inherit the premutation from
their mothers have the population-level risk for POF,
whereas women with a PIP have an excess risk for POF.
Further studies should address the behavior of PIPs dur-
ing early embryonal and germinal development in the
female fetus.
Acknowledgments
We would like to thank all the women who participated in
this study, Prof. Hans M. W. M. Merkus for his support, and
Meyke Schouten for data processing and statistical assistance.
The expert technical assistance of the laboratory technicians
and the help of the secretaries are acknowledged. The Zorg
Onderzoek Nederland Foundation is acknowledged for finan-
cial support. Thanks also to Prof. Han G. Brunner for critically
reading the manuscript.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim (for fragile X syndrome [MIM
309550])
References
Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden
JJ, Yang KT, Lee C, Hudson R, et al (1999) Fragile X pre-
mutation is a significant risk factor for premature ovarian
failure: the International Collaborative POF in Fragile X
study—preliminary data. Am J Med Genet 83:322–325
Ba¨chner D, Manca A, Steinbach P, Wo¨hrle D, Just W, Vogel
W, Hameister H, et al (1993) Enhanced expression of the
murine FMR1 gene during germ cell proliferation suggests
a special function in both the male and the female gonad.
Hum Mol Genet 2:2043–2050
Conway GS, Payne NN, Webb J, Murray A, Jacobs PA (1998)
Fragile X premutation screening in women with premature
ovarian failure. Hum Reprod 13:1184–1187
Cooper DW (1971) Directed genetic change model for X chro-
mosome inactivation in eutherian mammals. Nature 230:
292–294
Coulam CB, Adamson SC, Annegers JF (1986) Incidence of
premature ovarian failure. Obstet Gynecol 67:604–606
Dorland M, van Kooij RJ, te Velde ER (1998) General aging
and ovarian aging. Maturitas 30:113–118
Dutch-Belgian Fragile X Consortium (1994) Fmr1 knockout
mice: a model to study fragile X mental retardation. Cell
78:23–33
Eichenlaub-Ritter U (1998) Genetics of oocyte ageing. Ma-
turitas 30:143–169
Epstein CJ, Smith S, Travis B, Tucker G (1978) Both X chro-
mosomes function before visible X-chromosome inactiva-
tion in female mouse embryos. Nature 274:500–503
Faddy MJ, Gosden RG (1996) A model confirming the decline
in follicle numbers to the age of menopause in women. Hum
Reprod 11:1484–1486
Feng Y, Lakkis L, Devys D, Warren ST (1995) Quantitative
comparison of FMR1 gene expression in normal and pre-
mutation alleles. Am J Hum Genet 56:106–113
Ginsburg J (1991) What determines the age at the menopause?
the number of ovarian follicles seems to be the most im-
portant factor. Br Med J 302:1288–1289
Gosden RG, Faddy MJ (1998) Biological bases of premature
ovarian failure. Reprod Fertil Dev 10:73–78
Imbert G, Feng Y, Nelson DL, Warren ST, Mandel JL (1998)
FMR1 and mutations in fragile syndrome: molecular biol-
ogy, biochemistry, and genetics. In: Wells RD, Warren ST
(eds) Genetic instabilities and hereditary neurological dis-
orders. Academic Press, New York, pp 27–53
418 Am. J. Hum. Genet. 66:413–418, 2000
Kenneson A, Cramer DW, Warren ST (1997) Fragile X pre-
mutations are not a major cause of early menopause. Am J
Hum Genet 61:1362–1369
Malter HE, Iber JC, Willemsen R, de Graaff E, Tarleton JC,
Leisti J, Warren ST, Oostra BA (1997) Characterization of
the full fragile X syndrome mutation in fetal gametes. Nat
Genet 15:165–169
Monesi V, Geremia R, D’Agostino A, Boitani C (1978) Bio-
chemistry of male germ cell differentiation in mammals:
RNA synthesis in meiotic and postmeiotic cells. Curr Top
Dev Biol 12:11–36
Murray A, Webb J, Grimley S, Conway G, Jacobs P (1998)
Studies of FRAXA and FRAXE in women with premature
ovarian failure. J Med Genet 35:637–640
Partington MW, Moore DY, Turner GM (1996) Confirmation
of early menopause in fragile X carriers. Am J Med Genet
64:370–372
Schwartz CE, Dean J, Howard-Peebles PN, Bugge M, Mik-
kelsen M, Tommerup N, Hull C, et al (1994) Obstetrical
and gynecological complications in fragile X carriers: a mul-
ticenter study. Am J Med Genet 51:400–402
Skuse DH, James RS, Bishop DV, Coppin B, Dalton P, Aamodt-
Leeper G, Bacarese-Hamilton M, et al (1997) Evidence from
Turner’s syndrome of an imprinted X-linked locus affecting
cognitive function. Nature 387:705–708
Tamanini F, Willemsen R, van Unen L, Bontekoe C, Galjaard
H, Oostra BA, Hoogeveen AT (1997) Differential expression
of FMR1, FXR1 and FXR2 proteins in human brain and
testis. Hum Mol Genet 6:1315–1322
Thomas CM, Corbey RS, Rolland R (1977) Assessment of
unconjugated oestradiol and progesterone serum levels
throughout pregnancy in normal women and in womenwith
hyperprolactinaemia, who conceived after bromocriptine
treatment. Acta Endocrinol (Copenh) 86:405–414
Uzielli ML, Guarducci S, Lapi E, Cecconi A, Ricci U, Ricotti
G, Biondi C, et al. (1999) Premature ovarian failure (POF)
and fragile X premutation females: from POF to fragile X
carrier identification, from fragile X carrier diagnosis to POF
association data. Am J Med Genet 84:300–303
van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van
Zonneveld P, Braat DD (1999) Familial idiopathic prema-
ture ovarian failure: an overrated and underestimated ge-
netic disease? Hum Reprod 14:2455–2459
Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DPA,
Pizutti A, Reiner O, et al (1991) Identification of a gene
(FMR-1) containing a CGG repeat coincident with a break-
point cluster region exhibiting length variation in fragile X
syndrome. Cell 65:905–914
West JD, Frels WI, Chapman VM, Papaioannou VE (1977)
Preferential expression of the maternally derived X chro-
mosome in the mouse yolk sac. Cell 12:873–882
Willemsen R, Oosterwijk JC, Los FJ, Galjaard H, Oostra BA
(1996) Prenatal diagnosis of fragile X syndrome. Lancet
348:967–968
